Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion

Eye (Basingstoke)

Volumn 27, Issue 7, 2013, Pages 816-822

  Mayer, W J ^a   Wolf, A ^a   Kernt, M ^a   Kook, D ^a   Kampik, A ^a   Ulbig, M ^a   Haritoglou, C ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bevacizumab; Dexamethasone; Macular edema; Retinal vein occlusion

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE;

AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CATARACT EXTRACTION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL TRIAL; CYCLOPHOTOCOAGULATION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; HUMAN; INTRAOCULAR HEMORRHAGE; INTRAOCULAR PRESSURE; INTRAVITREAL HEMORRHAGE; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; RECURRENT DISEASE; RETINA DETACHMENT; RETINA MACULA EDEMA; SCLERAL BUCKLE; SIDE EFFECT; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84880269346     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2013.79     Document Type: Article

References (30)

1. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008; 33(2): 111-131.
2. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes 1998; 47(12): 1953-1959.
3. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008; 16(4): 791-799.
4. Shahsuvaryan ML, Melkonyan AK. Central retinal vein occlusion risk profile: a case-control study. Eur J Ophthalmol 2003; 13(5): 445-452.
5. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117(6): 1124-33 e1.
6. Haller JA, Bandello F, Belfort Jr, R, Blumenkranz MS, Gillies M, Heier J et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117(6): 1134-1146 e3.
7. Haller JA, Bandello F, Belfort Jr, R, Blumenkranz MS, Gillies M, Heier J et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118(12): 2453-2460.
8. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118(8): 1594-1602.
9. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118(10): 2041-2049.
10. Mayer WJ, Remy M, Wolf A, Kook D, Kampik A, Ulbig M et al. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant vs dexamethasone implant monotherapy for retinal vein occlusion with macular edema. Ophthalmologica 2012; 228(2): 110-116.
11. Group TCVOS. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995; 102(10): 1425-1433.
12. Group TBVOS. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984; 98(3): 271-282.
13. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118(4): 445-450.
14. Kaneda S, Miyazaki D, Sasaki S, Yakura K, Terasaka Y, Miyake K et al. Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment. Invest Ophthalmol Vis Sci 2011; 52(6): 2982-2988.
15. Ki IY, Arimura N, Noda Y, Yamakiri K, Doi N, Hashiguchi T et al. Stromal-derived factor-1 and inflammatory cytokines in retinal vein occlusion. Curr Eye Res 2007; 32(12): 1065-1072.
16. Noma H, Funatsu H, Harino S, Mimura T, Eguchi S, Hori S. Vitreous inflammatory factors in macular edema with central retinal vein occlusion. Jpn J Ophthalmol 2011; 55(3): 248-255.
17. Noma H, Funatsu H, Mimura T, Shimada K. Increase of aqueous inflammatory factors in macular edema with branch retinal vein occlusion: a case control study. J Inflamm (Lond) 2010; 7: 44.
18. Okunuki Y, Usui Y, Katai N, Kezuka T, Takeuchi M, Goto H et al. Relation of intraocular concentrations of inflammatory factors and improvement of macular edema after vitrectomy in branch retinal vein occlusion. Am J Ophthalmol 2011; 151(4): 610-616 e1.
19. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117(6): 1102-1112 e1.
20. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114(12): 2179-2182.
21. Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 2012; 119(12): 2587-2591.
22. Stahl A, Agostini H, Hansen LL, Feltgen N. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 2007; 245(10): 1429-1436.
23. Kriechbaum K, Prager F, GeitzenauerW, Benesch T, Schutze C, Simader C et al. Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year. Ophthalmology 2009; 116(12): 2415-2421.
24. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998; 341(2-3): 309-315.
25. Guthoff R, Meigen T, Hennemann K, Schrader W. Comparison of bevacizumab and triamcinolone for treatment of macular edema secondary to branch retinal vein occlusion in a pair-matched analysis. Ophthalmologica 2010; 224(5): 319-324.
26. Hu YJ. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye (Lond) 2010; 24(8): 1414, author reply 1414-1415.
27. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009; 127(9): 1115-1128.
28. Shroff D, Bhargava A, Sharma B, Gupta C, Shroff C. Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2010; 248(8): 1203.
29. Nabih M, Peyman GA, Tawakol ME, Naguib K. Toxicity of high-dose intravitreal dexamethasone. Int Ophthalmol 1991; 15(4): 233-235.
30. Singer MA, Bell DJ, Woods P, Pollard J, Boord T, Herro A et al. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion. Retina 2012; 32(7): 1289-1294.